We thank this reviewer for his or her responses and recognition that DNL343 features a promising potential as treatment for neurodegenerative diseases. Although our studies share some similarities to Wong et al., eLife DNL343 can be an investigational CNS-penetrant compact molecule ISR inhibitor intended to activate the eukaryotic initiation factor https://imt1b10986.mdkblog.com/33900682/the-5-second-trick-for-abbv-744